Q2 EBIT in line; capex higher on Phase 2 preparations Continued strong biological performance for Batch #1 Operational metrics support further case de-risking ahead
Ticking off significant milestone; first smolt in pool The puzzle pieces are coming together in the short-term... …with important months ahead to show proof-of-concept
We expect limited est. changes to consensus Successful testing of all vital pool functions during Q4 On track for smolt release in Q2’22, we reiterate BUY